15 MAR 2021 · February was a stunning season. Beats strongly overwhelmed misses by a record margin versus recent history. February was broadly a story of cyclicals outperforming overly-fearful valuations similar to August. Particularly impressive were Large-caps and domestic cyclicals as expected (Retail, Financials, traditional Industrials). Morgans Equity Strategist Tom Sartor discusses the outcomes, hits and misses for reporting season 1H21. Check out more from Morgans: Visit the Morgans website: www.morgans.com.au Check out our blog: www.morgans.com.au/Blog On Facebook: www.facebook.com/MorgansAU On Instagram: www.instagram.com/Morgans.Australia On Twitter: twitter.com/MorgansAU

23 FEB 2021 · Morgans Senior Analyst, Dr. Derek Jellinek, discusses the Healthcare Sector ahead of the February 2020 Reporting Season. In this update, Derek also highlights his thoughts on ResMed (ASX:RMD), CSL (ASX:CSL) and Ramsay Healthcare (ASX:RHC), considering their recent short-term price decline. Check out more from Morgans: Visit the Morgans website: www.morgans.com.au Check out our blog: www.morgans.com.au/Blog On Facebook: www.facebook.com/MorgansAU On Instagram: www.instagram.com/Morgans.Australia On Twitter: twitter.com/MorgansAU #Healthcare #Stocks #ReportingSeason

23 FEB 2021 · Andrew Harding Managing Director of Aurizon (ASX:AZJ) discusses company results for 1H21 with the Morgans network. Check out more from Morgans: Visit the Morgans website: www.morgans.com.au Check out our blog: www.morgans.com.au/Blog On Facebook: www.facebook.com/MorgansAU On Instagram: www.instagram.com/Morgans.Australia On Twitter: twitter.com/MorgansAU #Reportingseason21​ #Stocks​ #Analysis